Low-dose total skin electron beam therapy as an effective modality to reduce disease burden in patients with mycosis fungoides: Results of a pooled analysis from 3 phase-II clinical trials  

Oleh:

Hoppe, Richard T. ; Harrison, Cameron ; Tavallaee, Mahkam ; Bashey, Sameer ; Sundram, Uma

Jenis: Article from Journal - ilmiah internasional
Dalam koleksi: JAAD: Journal of the American Academy of Dermatology (keterangan: ada di ClinicalKey) vol. 72 no. 02 (Feb. 2015), page 286–292 .
Topik: cutaneous lymphoma; low-dose total skin electron beam therapy; radiotherapy; T-cell lymphoma; total skin electron beam therapy

Ketersediaan

Perpustakaan FK Nomor Panggil: J15.K Non-tandon: tidak ada Tandon: 1

Lihat Detail Induk

Isi artikel

Background Standard-dose (36-Gy) total skin electron beam therapy (TSEBT) is a highly effective treatment in mycosis fungoides. However, the regimen is time-intensive and may be associated with significant toxicity. Objective We sought to evaluate the efficacy and tolerability associated with low-dose (12-Gy) TSEBT. Methods Data from 3 clinical trials using low-dose (12-Gy) TSEBT were pooled. In all trials, TSEBT-naïve patients with stage IB to IIIA mycosis fungoides were treated with TSEBT (12 Gy, 1 Gy per fraction over 3 weeks). The primary end point was clinical response rate. Secondary end points included time to response and duration of clinical benefit. Results In all, 33 patients enrolled. Eighteen were male; stages were 22 IB, 2 IIA, 7 IIB, and 2 IIIA. Overall response rate was 88% (29/33), including 9 patients with complete response. Median time to response was 7.6 weeks (3-12.4 weeks). Median duration of clinical benefit was 70.7 weeks (95% confidence interval 41.8-133.8 weeks). Toxicities from TSEBT were mild and reversible. Limitations Conclusions are limited because of the small number of patients. Conclusions Low-dose TSEBT provides reliable and rapid reduction of disease burden in patients with mycosis fungoides, which could be administered safely multiple times during the course of a patient's disease with acceptable toxicity profile.

Opini Anda

Klik untuk menuliskan opini Anda tentang koleksi ini!

Kembali